InvestSMART

Antisense Therapeutics Limited (ASX: ANP) - Announcements

Current share price for ANP : $0.058 0.003 (4.92%)+

ASX company news and announcements for Antisense Therapeutics Limited (ANP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Antisense Therapeutics Limited (ANP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Antisense Therapeutics Limited (ANP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Antisense Therapeutics Limited (ANP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$52 ATL1102 Early Access Program Update 12 Oct 2015 9:30AM $0.080 $0.058 fallen by 27.50%
$52 Appendix 4G 30 Sep 2015 6:18PM $0.086 $0.058 fallen by 32.56%
$52 Annual Report to shareholders 30 Sep 2015 6:17PM $0.086 $0.058 fallen by 32.56%
$52 Corporate Presentation 14 Sep 2015 9:28AM $0.076 $0.058 fallen by 23.68%
$52 ATL1103 (COR-004) Higher Dose Study - Dosing Commenced 9 Sep 2015 9:05AM $0.079 $0.058 fallen by 26.58%
$52 ATL1103 / COR-004 4 Sep 2015 9:59AM $0.083 $0.058 fallen by 30.12%
$52 ATL1103/COR-004 - Cortendo NASDAQ IPO Prospectus 3 Sep 2015 9:56AM $0.089 $0.058 fallen by 34.83%
$52 ANP Licensing Partner Cortendo Announces NASDAQ IPO Filing 1 Sep 2015 9:18AM $0.082 $0.058 fallen by 29.27%
$52 Appendix 4E and Full Year Audited Statutory Accounts 24 Aug 2015 9:36AM $0.086 $0.058 fallen by 32.56%
$52 ANP to present at Canary Networks Investor Roadshow 18 Aug 2015 8:58AM $0.087 $0.058 fallen by 33.33%
$52 ANP Licensing Partner for ATL1103 Cortendo Files Prospectus 10 Aug 2015 9:19AM $0.090 $0.058 fallen by 35.56%
$52 ANP Licensing Partner Cortendo US IPO Plans 21 Jul 2015 11:25AM $0.100 $0.058 fallen by 42%
$52 Change of Director's Interest Notice (RM) 20 Jul 2015 9:42AM $0.120 $0.058 fallen by 51.67%
$52 Change of Director's Interest Notice (RM) 17 Jul 2015 9:05AM $0.110 $0.058 fallen by 47.27%
$52 ATL1102 Update 14 Jul 2015 9:23AM $0.100 $0.058 fallen by 42%
$52 Appendix 4C - quarterly 6 Jul 2015 9:36AM $0.115 $0.058 fallen by 49.57%
$52 ATL1103 for Cancer and Diabetic Complications Presentation 15 Jun 2015 9:29AM $0.105 $0.058 fallen by 44.76%
$52 Corporate Presentation 4 Jun 2015 10:11AM $0.110 $0.058 fallen by 47.27%
$52 Becoming a substantial holder 2 Jun 2015 9:48AM $0.110 $0.058 fallen by 47.27%
$52 Cleansing Notice 28 May 2015 9:34AM $0.110 $0.058 fallen by 47.27%
$52 ATL1102 Early Access Program Presentation 27 May 2015 9:20AM $0.125 $0.058 fallen by 53.60%
$52 ATL1102 Early Access Program for Patients with MS 27 May 2015 9:10AM $0.125 $0.058 fallen by 53.60%
$52 Change of registry address 15 May 2015 5:20PM $0.130 $0.058 fallen by 55.38%
$52 Appendix 3B 15 May 2015 9:19AM $0.150 $0.058 fallen by 61.33%
$52 Licensing Agreement for ATL1103 for Acromegaly 15 May 2015 9:19AM $0.150 $0.058 fallen by 61.33%

451 - 475 of 707 results

Page 19 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.